These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30875673)

  • 21. [Efficacy of escitalopram and severity of depression: new data].
    Spadone C
    Encephale; 2009 Dec; 35(6):577-85. PubMed ID: 20004289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder.
    Tafseer S; Gupta R; Ahmad R; Jain S; Bhatia MS; Gupta LK
    Pharmacol Biochem Behav; 2021 Jan; 200():173073. PubMed ID: 33186562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex.
    Tian S; Sun Y; Shao J; Zhang S; Mo Z; Liu X; Wang Q; Wang L; Zhao P; Chattun MR; Yao Z; Si T; Lu Q
    Hum Brain Mapp; 2020 Apr; 41(5):1249-1260. PubMed ID: 31758634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors predicting relapse in elderly patients with major depressive disorder treated with escitalopram in an outpatient setting.
    Dolberg O; Larsson Lönn S; Kvist K
    Curr Med Res Opin; 2014 Jul; 30(7):1301-7. PubMed ID: 24628498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain derived neurotrophic factor (BDNF) levels in depressed women treated with open-label escitalopram.
    Ladea M; Bran M
    Psychiatr Danub; 2013 Jun; 25(2):128-32. PubMed ID: 23793276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naïve patients with first major depression episode.
    Karlović D; Serretti A; Jevtović S; Vrkić N; Serić V; Peleš AM
    J Psychiatr Res; 2013 Feb; 47(2):162-7. PubMed ID: 23102630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Escitalopram versus Electric Current Therapy for Treating Depression Clinical Study (ELECT-TDCS): rationale and study design of a non-inferiority, triple-arm, placebo-controlled clinical trial.
    Brunoni AR; Sampaio-Junior B; Moffa AH; Borrione L; Nogueira BS; Aparício LV; Veronezi B; Moreno M; Fernandes RA; Tavares D; Bueno PV; Seibt O; Bikson M; Fraguas R; Benseñor IM
    Sao Paulo Med J; 2015; 133(3):252-63. PubMed ID: 26176930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in miRNA-132 and miR-124 levels in non-treated and citalopram-treated patients with depression.
    Fang Y; Qiu Q; Zhang S; Sun L; Li G; Xiao S; Li X
    J Affect Disord; 2018 Feb; 227():745-751. PubMed ID: 29689690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anhedonia among patients with Major Depressive Disorder: A comparison between patients on escitalopram and healthy controls.
    Ng CG; Wong SK; Loh HS; Yee A
    Clin Ter; 2014; 165(6):e384-90. PubMed ID: 25524191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM; Azorin JM; Despiegel N; Verpillat P
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial.
    Bretlau LG; Lunde M; Lindberg L; Undén M; Dissing S; Bech P
    Pharmacopsychiatry; 2008 Mar; 41(2):41-7. PubMed ID: 18311683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
    Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T
    Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients.
    Dvojkovic A; Nikolac Perkovic M; Sagud M; Nedic Erjavec G; Mihaljevic Peles A; Svob Strac D; Vuksan Cusa B; Tudor L; Kusevic Z; Konjevod M; Zivkovic M; Jevtovic S; Pivac N
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110016. PubMed ID: 32534176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.